"International Vaccine Institute" from_date:2012

Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015. Middle East respiratory syndrome (MERS) remains a serious international public health threat. With the goal of accelerating the development of countermeasures against MERS coronavirus (MERS-CoV ), funding agencies, nongovernmental organizations, and researchers across the world assembled in Riyadh, Saudi Arabia, on November 14-15, 2015, to discuss vaccine development challenges. The meeting was spearheaded by the Saudi Ministry of Health and co-organized by the International Vaccine Institute, South Korea. Accelerating the development of a preventive vaccine requires a better understanding

Profile: International Vaccine Institute (IVI)

Healthcare Limited DNA plasmid vaccine Phase 1 / 2 CTRI/2020/07/026352 15. DNA Vaccine (GX-19) Genexine Consortium DNA Vaccine (GX-19) Phase 1 / 2 NCT04445389 16. Whole-Virion Inactivated Bharat Biotech Whole-Virion Inactivated Phase 1 / 2 NCT04471519 17. INO-4700 Inovio Pharmaceuticals/ International Vaccine Institute DNA plasmid vaccine with electroporation Phase 1 / 2 NCT04447781 18. RBD-based

-19) Genexine Consortium DNA Vaccine (GX-19) Phase 1 / 2 NCT04445389 16. Whole-Virion Inactivated Bharat Biotech Whole-Virion Inactivated Phase 1 / 2 NCT04471519 17. INO-4700 Inovio Pharmaceuticals/ International Vaccine Institute DNA plasmid vaccine with electroporation Phase 1 / 2 NCT04447781 18. RBD-based Kentucky Bioprocessing, Inc RBD-based Phase 1 / 2 NCT04473690 19. mRNA Arcturus

analyses in future trials on dengue vaccines. The Philippine Department of Health, Hanako Foundation, WHO, Swedish International Development Cooperation Agency, International Vaccine Institute, University of North Carolina, and US National Institute of Allergy and Infectious Diseases.

,Ondrej Mach3 ,Roland W Sutter3 ,K Zaman1 Affiliations Expand Affiliations * 1 International Centre for Diarrheal Disease, Bangladesh (icddr, b), Dhaka, Bangladesh. * 2 International Vaccine Institute, Seoul, South Korea. * 3 World Health Organization, Geneva, Switzerland. * 4 Centers for Disease Control and Prevention, Atlanta, USA. * PMID: 35575051 * DOI: 10.1093/infdis/jiac205 Item in Clipboard ahead of print. Authors Asma B Aziz1 2 ,Harish Verma3 ,Visalakshi Jeyaseelan3 ,Yunus Md1 ,Samarea Nowrin1 ,Deborah D Moore4 ,Bernardo A Mainou4 ,Ondrej Mach3 ,Roland W Sutter3 ,K Zaman1 Affiliations * 1 International Centre for Diarrheal Disease, Bangladesh (icddr, b), Dhaka, Bangladesh. * 2 International Vaccine Institute, Seoul, South Korea. * 3 World Health Organization, Geneva, Switzerland. * 4

would benefit the most from vaccination, but the sensitivity of the IgG ELISA was much lower in this group than in those with a multitypic profile. Philippine Department of Health, Hanako Foundation, WHO, Swedish International Development Cooperation Agency through the International Vaccine Institute, and University of North Carolina, Chapel Hill, NC, USA.

since the foundation's inception. At the turn of the century, early efforts focused on characterizing the burden of disease in Asia and evaluating use of the available Vi-polysaccharide vaccines through the Diseases of the Most Impoverished projects at the International Vaccine Institute (IVI). More recent efforts have centered on supporting development of typhoid conjugate vaccines and expanding

using on-site and centralized monitoring methods, and a dedicated monitoring team was formed. The core activities were monitored on-site in each country at least twice per year and the SETA databases were monitored centrally as a collaborative effort between the International Vaccine Institute and study sites. Monthly reports were generated for key indicators and used to guide risk-based monitoring

%, -220 to 35). A single dose of the inactivated whole-cell OCV offered protection to older children and adults that was sustained for at least 2 years. The absence of protection of young children might reflect a lesser degree of pre-existing natural immunity in this age group. Bill & Melinda Gates Foundation to the International Vaccine Institute.

since 2001; the demand for this vaccine from affected countries has however been very low, due to various factors including vaccine price and mode of administration. The low demand for the vaccine and limited commercial incentives to invest in research and development of vaccines for developing country markets has kept the global supply of OCVs down. Since 1999, the International Vaccine Institute has

and the vaccine industry from emerging countries to the growing global vaccine market, by improving the supply base from manufacturers in developing countries and contributing to 58% of doses, were highlighted. The Coalition for Epidemic Preparedness Innovations (CEPI), the International Vaccine Institute (IVI) and others reported on new strategies to ensure speedy progress in preclinical and clinical

approvals for this protocol were obtained by the Institutional Review Board of the International Vaccine Institute (No. 2016-0003) and by all collaborating institutions of participating countries. It is anticipated to disseminate findings from this study through publication on a peer-reviewed journal.

measures. The Typhoid Fever Surveillance in Africa Program (TSAP) was established by the International Vaccine Institute to obtain comparable incidence data on typhoid fever and invasive nontyphoidal Salmonella (iNTS) disease in sub-Saharan Africa through standardized surveillance in multiple countries. Standardized procedures were developed and deployed across sites for study site selection, patient

Alliance), Royal College of Obstetrics & Gynaecology, international vaccine institute, Royal College of Midwives, UK Teratology Information Service, Tommy’s, NCT, AIMS, Antenatal Results & Choices, UK Health Security Agency, ECDC, EMA, CDC, Public Health England, Maternity Action and MBRRACE-UK) to identify additional relevant reports. Additionally, Google Scholar will be used to identify relevant

that will be shared with University of Oxford, International Vaccine Institute (IVI), Seoul, Republic of Korea, Ragon Institute, Harvard School of Medicine, USA, National Institute of Health (NIH) Pakistan will have multi-layered security with several layers of encryption to protect data. Blood samples from patients enrolled will be stored at our research office in Infectious disease research laboratory at Aga Khan

Recruitment Status : Completed First Posted : January 6, 2014 Last Update Posted : March 20, 2018 Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh Collaborators: International Vaccine Institute Government of Bangladesh Information provided by (Responsible Party): International Centre for Diarrhoeal Disease Research, Bangladesh * Study Details * Tabular View * No Results Posted International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Dhaka, Bangladesh, 1212 Sponsors and Collaborators International Centre for Diarrhoeal Disease Research, Bangladesh International Vaccine Institute Government of Bangladesh More InformationGo to Top of Page Study Description Study Design Arms and Interventions Outcome

. ClinicalTrials.gov Identifier: NCT03747770 Recruitment Status : Enrolling by invitation First Posted : November 20, 2018 Last Update Posted : April 22, 2020 Sponsor: International Vaccine Institute Collaborator: Ministry of Health, Thailand Information provided by (Responsible Party): International Vaccine Institute * Study Details the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03747770 Locations Thailand Ministry of Public Health Bangkok, Chang Wat Nonthaburi, Thailand, 11000 Sponsors and Collaborators International Vaccine Institute Ministry of Health, Thailand Investigators

: Active, not recruiting First Posted : March 14, 2018 Last Update Posted : April 20, 2020 Sponsor: University of the Philippines Collaborators: Department of Health, Philippines World Health Organization Research Institute for Tropical Medicine, Philippines University of North Carolina La Jolla Institute for Allergy & Immunology International Vaccine Institute Information provided by (Responsible Organization Research Institute for Tropical Medicine, Philippines University of North Carolina La Jolla Institute for Allergy & Immunology International Vaccine Institute Investigators Principal Investigator: Jacqueline L. Deen, MD UPM-NIH, Institute of Child Health and Human Development More InformationGo to Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility

Recruitment Status : Completed First Posted : April 18, 2012 Last Update Posted : September 25, 2013 Sponsor: Sachin Desai Collaborators: National Institute of Cholera and Enteric Diseases, India Indian Council of Medical Research Information provided by (Responsible Party): Sachin Desai, International Vaccine Institute * Study Details * Tabular View * No Results Posted * Disclaimer * How to Read Kanungo, MBBS National Institute of Cholera and Enteric Diseases, India More InformationGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Responsible Party: Sachin Desai, ASSOCIATE RESEARCH SCIENTIST, International Vaccine Institute ClinicalTrials.gov Identifier: NCT01579448